352 related articles for article (PubMed ID: 34229609)
1. Complement activation and blockade in massive post-partum haemorrhage, thrombotic microangiopathy and acute kidney injury: a case report.
Guzzo G; Kissling S; Pantaleo G; Pascual M; Sadallah S; Teta D
BMC Nephrol; 2021 Jul; 22(1):252. PubMed ID: 34229609
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy associated TMA in 13-year-old patient successfully treated with Eculizumab: case report.
Cody E; Claes D; Taylor V; Erkan E
BMC Nephrol; 2022 Apr; 23(1):147. PubMed ID: 35428247
[TBL] [Abstract][Full Text] [Related]
3. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.
Grall M; Daviet F; Chiche NJ; Provot F; Presne C; Coindre JP; Pouteil-Noble C; Karras A; Guerrot D; François A; Benhamou Y; Veyradier A; Frémeaux-Bacchi V; Coppo P; Grangé S
BMC Nephrol; 2021 Jul; 22(1):267. PubMed ID: 34284729
[TBL] [Abstract][Full Text] [Related]
4. Post-partum acute kidney injury: sorting placental and non-placental thrombotic microangiopathies using the trajectory of biomarkers.
Meibody F; Jamme M; Tsatsaris V; Provot F; Lambert J; Frémeaux-Bacchi V; Ducloy-Bouthors AS; Jourdain M; Delmas Y; Perez P; Darmian J; Wynckel A; Rebibou JM; Coppo P; Rafat C; Rondeau E; Frimat L; Hertig A
Nephrol Dial Transplant; 2020 Sep; 35(9):1538-1546. PubMed ID: 30805631
[TBL] [Abstract][Full Text] [Related]
5. Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.
Ikeda T; Okumi M; Unagami K; Kanzawa T; Sawada A; Kawanishi K; Omoto K; Ishida H; Tanabe K
Nephrology (Carlton); 2016 Jul; 21 Suppl 1():35-40. PubMed ID: 26970541
[TBL] [Abstract][Full Text] [Related]
6. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.
Kello N; Khoury LE; Marder G; Furie R; Zapantis E; Horowitz DL
Semin Arthritis Rheum; 2019 Aug; 49(1):74-83. PubMed ID: 30598332
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab deposits in vessel walls in thrombotic microangiopathy.
Cassol CA; Brodsky SV; Satoskar AA; Blissett AR; Cataland S; Nadasdy T
Kidney Int; 2019 Sep; 96(3):761-768. PubMed ID: 31345584
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.
Schoettler M; Lehmann L; Li A; Ma C; Duncan C
Biol Blood Marrow Transplant; 2019 May; 25(5):e163-e168. PubMed ID: 30639820
[TBL] [Abstract][Full Text] [Related]
9. Thrombotic Microangiopathy Secondary to Systemic Sclerosis with Severe Complement Activation Not Responsive to Eculizumab: A Case Report.
Nakamura M; Abe T; Ochiai H
Am J Case Rep; 2022 Jun; 23():e936116. PubMed ID: 35671252
[TBL] [Abstract][Full Text] [Related]
10. Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab.
Jodele S; Dandoy CE; Lane A; Laskin BL; Teusink-Cross A; Myers KC; Wallace G; Nelson A; Bleesing J; Chima RS; Hirsch R; Ryan TD; Benoit S; Mizuno K; Warren M; Davies SM
Blood; 2020 Mar; 135(13):1049-1057. PubMed ID: 31932840
[TBL] [Abstract][Full Text] [Related]
11. Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report.
Abe T; Sasaki A; Ueda T; Miyakawa Y; Ochiai H
Medicine (Baltimore); 2017 Feb; 96(6):e6056. PubMed ID: 28178155
[TBL] [Abstract][Full Text] [Related]
12. Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.
Begum F; Khan N; Boisclair S; Malieckal DA; Chitty D
Am J Ther; 2023 May; 30(3):e209-e219. PubMed ID: 37104648
[TBL] [Abstract][Full Text] [Related]
13. Compassionate Use Narsoplimab for Severe Refractory Transplantation-Associated Thrombotic Microangiopathy in Children.
Schoettler ML; Patel S; Bryson E; Deeb L; Watkins B; Qayed M; Chandrakasan S; Fitch T; Silvis K; Jones J; Chonat S; Williams KM
Transplant Cell Ther; 2024 Mar; 30(3):336.e1-336.e8. PubMed ID: 38145741
[TBL] [Abstract][Full Text] [Related]
14. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.
Jodele S; Fukuda T; Vinks A; Mizuno K; Laskin BL; Goebel J; Dixon BP; Teusink A; Pluthero FG; Lu L; Licht C; Davies SM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):518-25. PubMed ID: 24370861
[TBL] [Abstract][Full Text] [Related]
15. The use of eculizumab in Capnocytophaga canimorsus associated thrombotic microangiopathy: a case report.
Bjørkto MH; Barratt-Due A; Nordøy I; Dörje C; Galteland E; Lind A; Hilli A; Aukrust P; Mjøen G
BMC Infect Dis; 2021 Feb; 21(1):137. PubMed ID: 33526010
[TBL] [Abstract][Full Text] [Related]
16. [HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review].
Mancini A; Ardissino G; Angelini P; Giancaspro V; La Raia E; Nisi M; Proscia A; Tarantino G; Vitale O; D'elia F
G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983177
[TBL] [Abstract][Full Text] [Related]
17. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.
Jodele S; Fukuda T; Mizuno K; Vinks AA; Laskin BL; Goebel J; Dixon BP; Chima RS; Hirsch R; Teusink A; Lazear D; Lane A; Myers KC; Dandoy CE; Davies SM
Biol Blood Marrow Transplant; 2016 Feb; 22(2):307-315. PubMed ID: 26456258
[TBL] [Abstract][Full Text] [Related]
18. Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination.
Jodele S; Dandoy CE; Danziger-Isakov L; Myers KC; El-Bietar J; Nelson A; Wallace G; Teusink-Cross A; Davies SM
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1337-1340. PubMed ID: 27060440
[TBL] [Abstract][Full Text] [Related]
19. Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?
Jodele S; Dandoy CE; Sabulski A; Koo J; Lane A; Myers KC; Wallace G; Chima RS; Teusink-Cross A; Hirsch R; Ryan TD; Benoit S; Davies SM
Transplant Cell Ther; 2022 Jul; 28(7):392.e1-392.e9. PubMed ID: 35490975
[TBL] [Abstract][Full Text] [Related]
20. Complement Activation and Thrombotic Microangiopathy Associated With Monoclonal Gammopathy: A National French Case Series.
Martins M; Bridoux F; Goujon JM; Meuleman MS; Ribes D; Rondeau E; Guerry MJ; Delmas Y; Levy B; Ducloux D; Kandel-Aznar C; Le Fur A; Garrouste C; Provot F; Gibier JB; Thervet E; Bruneval P; Rabant M; Karras A; Dragon Durey MA; Fremeaux-Bacchi V; Chauvet S
Am J Kidney Dis; 2022 Sep; 80(3):341-352. PubMed ID: 35217094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
